| pubmed-article:602503 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:602503 | lifeskim:mentions | umls-concept:C0156543 | lld:lifeskim |
| pubmed-article:602503 | lifeskim:mentions | umls-concept:C0032980 | lld:lifeskim |
| pubmed-article:602503 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:602503 | lifeskim:mentions | umls-concept:C0205435 | lld:lifeskim |
| pubmed-article:602503 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:602503 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:602503 | lifeskim:mentions | umls-concept:C0442117 | lld:lifeskim |
| pubmed-article:602503 | pubmed:issue | 22 | lld:pubmed |
| pubmed-article:602503 | pubmed:dateCreated | 1978-3-10 | lld:pubmed |
| pubmed-article:602503 | pubmed:abstractText | The effectiveness of intramuscular 15-methyl-prostaglandin F2alpha (15-methyl-PGF2alpha) application for therapeutic abortion was studied in 16 women during the first and second trimester (12 to 17 weeks) of pregnancy. 250 microgram 15-methyl-PGF2alpha were administered initial and at intervals of 2 hours. Of the 16 subjects, 2 aborted completely, 13 aborted incompletely and 1 failed to abort. The mean abortion time for the 15 successful abortions was 11,25 hours and the mean 15-methyl-PGF2alpha dosage 1,35 mgs. Vomiting and diarrhea were the most prevalent side effects occurring in 12 of 16 patients. No serious complications occurred. In 9 women between 7 to 13 weeks of pregnancy a single intramuscular injection of 250 microgram 15-methyl-PGF2alpha was administered 11 to 13 hours prior to vacuum aspiration. All subjects had a gradual softening and dilatation of the cervix (5 to 8 mm). In 7 of 9 patients occurring gastro-intestinal side effects. Acute ascension was observed in 2 women after vacuum aspiration. All subjects had a gradual softning and dilatation of the cervix (5 to 8 mm). In 7 of 9 patients occurring gastro-intestinal side effects. Acute ascension was observed in 2 women after vacuum aspiration. Intramuscular administration of 15-methyl-PGF2alpha appears to be an effective abortifacient. Gastro-intestinal side effects can be reduced by antiemetic and antidiarrheal agents or lowering the initial dose of 15-methyl-PGF2alpha. | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:language | ger | lld:pubmed |
| pubmed-article:602503 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:602503 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:602503 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:602503 | pubmed:issn | 0044-4197 | lld:pubmed |
| pubmed-article:602503 | pubmed:author | pubmed-author:RudolfKK | lld:pubmed |
| pubmed-article:602503 | pubmed:author | pubmed-author:GöretzlehnerG... | lld:pubmed |
| pubmed-article:602503 | pubmed:author | pubmed-author:FrahmRR | lld:pubmed |
| pubmed-article:602503 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:602503 | pubmed:volume | 99 | lld:pubmed |
| pubmed-article:602503 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:602503 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:602503 | pubmed:pagination | 1356-60 | lld:pubmed |
| pubmed-article:602503 | pubmed:dateRevised | 2008-2-11 | lld:pubmed |
| pubmed-article:602503 | pubmed:otherAbstract | PIP: Use of 15-methyl-prostaglandin F2 alpha to induce therapeutic abortion in 25 women is described. Repeated intramuscular (im) injections resulted in complete abortion in 2 patients, and incomplete abortion in 13 others. A 16th patient failed to abort. In 9 women in the 7-13th week of pregnancy, a single im injection induced cervical softening and dilatation before vacuum aspiration. Diarrhea and vomiting occurred in 19 patients. The authors recommend the use of anti-emetics and anti-diarrheals, or a lower initial dose, to control side effects. Evidence indicates 15-methyl-prostaglandin F2 alpha is a successful abortifacient. | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-H... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-P... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-V... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-A... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-I... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-D... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-N... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-F... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-A... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-A... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-P... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-P... | lld:pubmed |
| pubmed-article:602503 | pubmed:meshHeading | pubmed-meshheading:602503-P... | lld:pubmed |
| pubmed-article:602503 | pubmed:year | 1977 | lld:pubmed |
| pubmed-article:602503 | pubmed:articleTitle | [Therapeutic induction of abortion in the 1st and 2nd trimesters with intramuscular 15-methyl-prostaglandin F2 alpha]. | lld:pubmed |
| pubmed-article:602503 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:602503 | pubmed:publicationType | English Abstract | lld:pubmed |
